SES
SES Networks has announced today that it is working with Virgin Voyages to provide its fleet with the industry’s leading high-speed, low-latency connectivity. The ultra-modern Wi-Fi service will be free for every sailor. That’s pretty fly for Wi-Fi!
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210223006270/en/
Virgin Voyages’ Lady Ships will boast incredible speeds, unprecedented reliability, and all the bandwidth passengers could possibly need thanks to SES Networks’ satellite-enabled Signature Cruise Solution . Sailors on board the fleet will be able to stream their favourite HD movies, game online without lag, and seamlessly keep posting to the ‘gram while living for the moment and getting their full dose of Vitamin Sea.
"SES Networks offers us unique, reliable capabilities that rival land speed connectivity," said Andy Schwalb, Chief Marine & Technology Officer at Virgin Voyages. "This service has played a critical role in the success of our inaugural events last year, while also enabling our crew to remain connected and close to their loved ones during this challenging time. We know our Sailors will enjoy this service during their voyage as they document their vacation and share with others."
"It’s a delight to work with partners like Virgin Voyages who are raising the bar in the industry. They’re creating a sea change in the cruise market and high-speed connectivity is critical to realising their sky high ambitions,” said Simon Maher, Vice President Global Sales, Cruise Maritime Services at SES Networks. “Through our ultra-fast, low-latency connectivity, we’re able to empower Virgin Voyages’ sailors with Pretty Fly for a WiFi at sea that’s even faster than most home broadband.”
SES Networks’ Signature Cruise Solution is an end-to-end service that combines SES’s low-latency O3b satellite constellation, its upcoming next-generation O3b mPOWER system and its highly reliable geostationary (GEO) fleet to ensure seamless connectivity across the globe. Both O3b and O3b mPOWER systems are operating in the medium earth orbit, around 8,000km above earth’s surface.
The O3b mPOWER, when operational in 2022, will deliver significant increase of flexibility and throughput, and can deliver multiple gigabits per second to any Virgin Voyage ship sailing anywhere on earth during seasonal peaks and in areas of high density.
Follow us on:
Twitter
| Facebook
| YouTube
| LinkedIn
| Instagram
Read our Blogs >
Visit the Media Gallery >
About SES
SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless connectivity around the world. As the leader in global content connectivity solutions, SES operates the world’s only multi-orbit constellation of satellites with the unique combination of global coverage and high performance, including the commercially-proven, low-latency Medium Earth Orbit O3b system. By leveraging a vast and intelligent, cloud-enabled network, SES is able to deliver high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES’s video network carries over 8,200 channels and has an unparalleled reach of 367 million households, delivering managed media services for both linear and non-linear content. The company is listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com .
About Virgin Voyages
Virgin Voyages is a new lifestyle travel brand focused on delivering irresistible cruise vacations. The brand currently has four ships on order with master shipbuilder Fincantieri and has operations in the US, UK and across Europe. Virgin Voyages’ first ship, Scarlet Lady was designed to reflect a yacht’s sleek luxury, offering the intimate, elevated experience of a boutique hotel at sea. Featuring spaces designed by some of the top names in contemporary interiors, Scarlet Lady is Adult-by-Design and a sanctuary at sea for the 18+ traveler. A dose of Vitamin Sea will be naturally intertwined across the entire ship, with well-being, relaxation and rejuvenation at the forefront. Scarlet Lady will also feature alluring entertainment and 20+ world-class intimate eateries on board. With a modern twist on luxury, coupled with discerning design, Virgin Voyages offers incredible value for its sailors, including unlimited access to all restaurants and eateries, group fitness classes, free WiFi and tips covered in the voyage fare.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210223006270/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release
New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom